Minimal Impact of the COVID-19 Pandemic on Disease Activity and Health-Related Quality of Life in Patients With Ankylosing Spondylitis Receiving Bimekizumab: Exploratory Analyses From a Phase 2b Open-Label Extension Study.
Philip C RobinsonPedro M MachadoNigil HaroonLianne S GenslerJohn D ReveilleVanessa TaiebThomas VauxCarmen FleurinckMarga OortgiesenNatasha de PeyrecaveAtul A DeodharPublished in: ACR open rheumatology (2022)
Disease activity and HRQoL remained stable during the COVID-19 pandemic in patients with AS receiving bimekizumab in the BE AGILE OLE, with no indication of negative effects on these outcomes.